4 Analysts Have This to Say About Forma Therapeutics Hldgs
Within the last quarter, Forma Therapeutics Hldgs (NASDAQ:FMTX) has observed the following analyst ratings:
This Analyst Predicts $700 For Broadcom, Plus RBC Capital Slashes PT On This Stock By 85%
Keybanc cut the price target for Broadcom Inc. (NASDAQ: AVGO) from $780 to $700. Broadcom shares rose 2.3% to $503.14 in pre-market trading.
Credit Suisse Downgrades Forma Therapeutics Hldgs to Neutral, Announces $20 Price Target
Credit Suisse analyst Tiago Fauth downgrades Forma Therapeutics Hldgs (NASDAQ:FMTX) from Outperform to Neutral and announces $20 price target.
HC Wainwright & Co. Downgrades Forma Therapeutics Hldgs to Neutral, Lowers Price Target to $20
HC Wainwright & Co. analyst Robert Burns downgrades Forma Therapeutics Hldgs (NASDAQ:FMTX) from Buy to Neutral and lowers the price target from $53 to $20.
Oppenheimer Downgrades Forma Therapeutics Hldgs to Perform
Oppenheimer analyst Mark Breidenbach downgrades Forma Therapeutics Hldgs (NASDAQ:FMTX) from Outperform to Perform.
Jefferies Downgrades Forma Therapeutics Hldgs to Hold, Lowers Price Target to $20
Jefferies analyst Maury Raycroft downgrades Forma Therapeutics Hldgs (NASDAQ:FMTX) from Buy to Hold and lowers the price target from $28 to $20.
Dow Turns Higher; Gold Down 1%
U.S. stocks pared losses, with the Dow Jones turning higher toward the end of trading on Thursday.
